Tramadol IV Opioid Gets Negative Vote From US FDA Advisory Panel

 
• By Brenda Sandburg
Tramadol
Joint US FDA advisory committee concludes data do not show the benefits of tramadol IV outweigh its risks. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers